The rise in prevalence of autoantibodies neutralizing type I interferons reaches a plateau in centenarians

The science

Original title

The rise in prevalence of autoantibodies neutralizing type I interferons reaches a plateau in centenarians.

Authors

Mørk N, Jensen JA, Bastard P et al.

Journal

Journal of human immunity

Published

Oct 27, 2026

Study type

Study

PMID

42944855 ↗

DOI

10.70962/jhi.20260143 ↗

Abstract

While autoantibodies (auto-Abs) neutralizing type I interferons (IFN-I) are relatively rare before the age of 65 (<1%), their prevalence reaches 2-3% between 70 and 80 years and >6% in individuals above 80 years in the general population. To assess the prevalence of IFN-I auto-Abs at the extreme end of human lifespan, we performed a multinational study of centenarians from four geographically and ethnically distinct cohorts collected in Denmark (n = 258), Colombia (n = 99), Australia (n = 281), and Japan (n = 300), comprising 938 individuals. Across cohorts, 51/938 centenarians (5.4%) harbored auto-Abs neutralizing IFN-I, ranging from 3.3% (Japan) to 9.1% (Colombia). We found that the prevalence of IFN-I auto-Abs levels off in centenarians compared with individuals ≥80 years from the general population, demonstrating that neutralizing IFN-I auto-Abs are not incompatible with longevity, despite conferring a risk of life-threatening viral infections. Yet, the plateau of their prevalence in centenarians suggests that they may not be beneficial for reaching exceptional longevity and may negatively impact mortality.

Read it on PubMed ↗